Published June 30, 2025
| Version v1
Journal article
Open
A Comparative Study of Efficacy and Safety of Intralesional Injections of Vitamin D3, MMR Vaccine and Acyclovir in Management of Cutaneous Warts
Authors/Creators
- 1. International Journal of Medical Science and Advanced Clinical Research (IJMACR)
Description
Abstract
Cutaneous warts, caused by human papillomavirus, are common benign skin lesions with various treatment options, including immunotherapy, which has gained attention for its ability to stimulate cell-mediated immunity and promote wart clearance. This study compared the efficacy and safety of intralesional injections of Vitamin D3, MMR vaccine, and acyclovir in the management of verruca vulgaris. A total of 105 patients were divided into three groups, each receiving intralesional injections of one of the treatments at two-week intervals, with a maximum of three sessions. The results showed that while initial improvements after the first session were comparable across all groups, significant differences emerged after the final session. The MMR group demonstrated superior efficacy, with 57.14% of patients achieving excellent improvement, com- pared to 28.57% in the Vitamin D3 group and 42.85% in the acyclovir group (p=0.00105). Additionally, the MMR group had the lowest proportion of patients with no improvement (11.42%), compared to the Vitamin D3 group (20%) and the acyclovir group (57.1%) (p=0.0045). Safety profiles also favored the MMR vaccine, which showed fewer adverse effects compared to Vitamin D3 and acyclovir. The findings suggest that intralesional MMR is a more effective and safer treatment option for cutaneous warts than intralesional Vitamin D3 or acyclovir. This supports the growing evidence for immunotherapy as a promising approach in managing cutaneous warts.
Files
NUPUR.pdf
Files
(911.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:cc8231979b43da204be527b5db1d8531
|
911.6 kB | Preview Download |
Additional details
Software
- Repository URL
- https://ijmacr.com/issue/archive_issue/61
References
- 1. James WD, Elston D, Berger T. Andrew's dis- eases of the skin E-book: clinical dermatology. Elsevier Health Sciences; 2011 Mar 21. 2. Al Aboud AM, Nigam PK. Wart. Treasure Island (FL): StatPearls Publishing; 2023. 3. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global bur- den of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J In- vest Dermatol 2014;134:1527-34. 4. Laxmisha C, Thappa DM, Jaisankar TJ. Viral warts-A clinico-epidemiological study. Indian J Dermatol 2003 Jul 1;48(3):142-5. 5. Sharma RC, Mendiratta V. Clinical profile of cu- taneous infections and infestations in the pae- diatric age group. Indian J Dermatol 1999 Oct 1;44(4):174-8. 6. Mursic I, Vcev A, Kotrulja L, Kuric I, Milavic T, Sustic N, et al. Treatment of verruca vul- garis in traditional medicine. Acta Clin Croat 2020;59:745-50. 7. Mattoo A, Bhatia M. Verruca vulgaris of the buc- cal mucosa: a case report. J Cancer Res Ther 2018;14:454-6. 8. Loo SK-F, Tang WY. Warts (non-genital). BMJ Clin Evid 2014;2014:1710. 9. Martin A, Thatiparthi A, Nourmohammadi N, Nguyen C, Sung C, Mesinkovska NA. Emerg- ing intralesional treatments for plantar warts: a systematic review. J Drugs Dermatol 2022 Dec 1;21(12):1322-9. 10. Aldahan AS, Mlacker S, Shah VV, Kamath P, Al- saidan M, Samarkandy S, et al. Efficacy of in- tralesional immunotherapy for the treatment of warts: a review of the literature. Dermatol Ther 2016;29:197-207. 11. Ju HJ, Park HR, Kim JY, Kim GM, Bae JM,Lee JH. Intralesional immunotherapy for non- genital warts: a systematic review and meta- analysis. Indian J Dermatol Venereol Leprol 2022;88:724-37. 12. Fields JR, Saikaly SK, Schoch JJ. Intralesional immunotherapy for pediatric warts: a review. Pediatr Dermatol 2020;37:265-71. 13. Chauhan PS, Mahajan VK, Mehta KS, Rawat R, Sharma V. The efficacy and safety of intrale- sional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of com- mon warts in adults. Indian Dermatol Online J 2019 Jan-Feb;10(1):19-26. 14. Elsayed A, Nassar A, Marei A, Hoseiny HAM, Alakad R. Intralesional Acyclovir: A potential therapeutic option for cutaneous warts. J Cutan Med Surg 2022 Jan-Feb;26(1):25-30. 15. Latif I, Sultan J, Aslam A, Hassan I, Devi R. Role of intralesional Vitamin D3 in the treatment of cutaneous warts. J Cutan Aesthet Surg 2021 Oct- Dec;14(4):404-8. 16. Mullen SA, Myers EL, Brenner RL, Nguyen KT, Harper TA, Welsh D, Keffer S, Mueller J, Whitley MJ. Systematic review of intralesional therapies for cutaneous warts. JID Innovations 2024 May 1;4(3):100264. 17. Lipke MM. An armamentarium of wart treat- ments. Clin Med Res 2006;4(4):273-93. 18. Nischal KC, Sowmya CS, Swaroop MR, Agrawal DP, Basavaraj HB, Sathyanarayana BD, et al. A novel modification of the autoimplantation therapy for the treatment of multiple, recurrent and palmoplantar warts. J Cutan Aesthet Surg 2012;5(1):26-9. 19. Bilgic A, Akman-Karakas A. Bleomycin ther- apy using multipuncture technique for resistant warts. Turk J Dermatol 2019;13:91-3. 20. Nimbalkar A, Pande S, Sharma R, BorkarM. Tuberculin purified protein derivative im- munotherapy in the treatment of viral warts. In- dian J Drugs Dermatol 2016;2(1):19. 21. Van Gasse TT, Miller. Incidence of verruca plantaris in a school population. Arch Paediatr 1958;75:279-84. 22. Khopkar US, Rajagopalan M, Chauhan AR, Kothari-Talwar S, Singhal PK, Yee K, et al. Preva- lence and burden related to genital warts in In- dia. Viral Immunol 2018;31(5):346-51. 23. Chandrashekar L, Thappa DM, Jaisankar TJ. Vi- ral warts—a clinico-epidemiological study. In- dian J Dermatol 2003;48:142-5. 24. Goldschmidt H, Kligman AM. Experimental inoculation of human with ectodermotropic virus. J Invest Dermatol 1958;31:175-8. 25. Oriel JD. Natural history of genital warts. Br J Vener Dis 1971;1:47. 26. IARC Working Group on the Evaluation of Car- cinogenic Risks to Humans. Human papillo- maviruses. Lyon (FR): International Agency for Research on Cancer; 2007. (IARC Monographs on the Evaluation of Carcinogenic Risks to Hu- mans, No. 90.) 1, Human Papillomavirus (HPV) Infection. Available from: https://www.ncbi. nlm. nih.gov/books/NBK321770/ 27. Morshed K, Polz-Gruszka D, Szymański M, Polz-Dacewicz M. Human papillomavirus (HPV)–structure, epidemiology and pathogen- esis. Otolaryngol Pol 2014;68(5):213-9. 28. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res 2017;772:3-12. 29. Gentles JC, Evans EGV. Foot infections in swim- ming baths. Br Med J 1973;3:260. 30. Vorsters A, Van Damme P, Bosch FX. HPV vac- cination: Are we overlooking additional oppor- tunities to control HPV infection and transmis- sion? Int J Infect Dis 2019;88:110-2. 31. Liu Z, Rashid T, Nyitray AG. Penises not re- quired: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sexual Health 2015;13(1):10-21. 32. Rock B, Naghashfar Z, Barnett N. Genital tract papillomavirus infection in children. Arch Der- matol 1986;122:1129-32. 33. Rathi S, Hajare SA, Jaiswal S, Agrawal S, Kherde A, Mishra D, et al. Pattern of sexually transmit- ted infections: A retrospective study from a ter- tiary care hospital in Central India. J Clin Diagn Res 2021;15(1). 34. Brentyans MH, Yung-Yue KA, Lee PC, Tyring SK. Human papillomavirus: a review. Dermatol Clin 2002;20:315-19. 35. Hammer A, Rositch A, Qeadan F, Gravitt PE, Blaakaer J. Age-specific prevalence of HPV 16/18 genotypes in cervical cancer: a system- atic review and meta-analysis. Int J Cancer 2016; 138 (12):2795-803. 36. Bacaj P, Burch D. Human papillomavirus in- fection of the skin. Arch Pathol Lab Med 2018 Jun;142(6):700-5. 37. Stanley MA, Sterling JC. Host responses to in- fection with human papillomavirus. Curr Probl Dermatol 2014;45:58-74. 38. Jablonska S, Orth G, Obalek S, Croissant O. Cuta- neous warts: Clinical, histologic, and virologic correlations. Clin Dermatol 1985;3(4):71-82. 39. Rübben A, Kalka K, Spelten B, Grußendorf- Conen EI. Clinical features and age distribution of patients with HPV 2/27/57-induced common warts. Arch Dermatol Res 1997;289(6):337-40. 40. Abeck D, Tetsch L, Lüftl M, Biedermann T. Extragenital cutaneous warts–clinical pre- sentation, diagnosis and treatment. JDDG: J der Deutschen Dermatol Gesellschaft 2019;17(6):613-34. 41. Thomas KK, Hughes JP, Kuypers JM. Concur- rent and sequential acquisition of different gen- ital human papillomavirus types. J Infect Dis 2000; 182:1097-102. 42. Goldstein BG, Goldstein AO, Morris-Jones R, Dellavalle RP, Levy ML, Rosen T, Ofori AO. Cuta- neous warts (common, plantar, and flat warts). UpToDate. Updated 7 Mar 2018; cited 29 Jan2019. 43. Asghar N, Asghar M, Rehman N, Afridi IU, Khalid S. Epidemiological and clinical pat- terns of viral warts presenting to dermatology OPD of Hayatabad Medical Complex, Peshawar: Epidemiological and clinical patterns of viral warts. J Pak Ass Dermatol 2022;32(1):78-84. 44. Albuquerque A, Medeiros R. New insights into the role of human papillomavirus in anal can- cer and anal wart development. Acta Cytologica 2019; 63 (2):118-23. 45. Lacarrubba F, Verzì AE, Quattrocchi E, Micali G. Cutaneous and anogenital warts. In: Atlas of Pe- diatric Dermatoscopy 2018. Springer, Cham. p. 35-44. 46. Kilic A, Ulku ME. Anogenital warts: an up- date on human papillomavirus, clinical man- ifestations, and treatment strategies. Mucosa 2019;2(2):30-40. 47. Myers DJ, Kwan E, Fillman EP. Epidermodyspla- sia verruciformis. 48. Moore S, Rady P, Tyring S. Acquired epider- modysplasia verruciformis: clinical presenta- tion and treatment update. Int J Dermatol 2021 Aug 17. 49. Al Rudaisat M, Cheng H. Dermoscopy features of cutaneous warts. Int J Gen Med 2021;14:9903- 12. 50. Aldana-Caballero A, Marcos-Tejedor F, Mayor- domo R. Diagnostic techniques in HPV infec- tions and the need to implement them in plan- tar lesions: A systematic review. Expert Rev Mol Diagn 2021;21(12):1341-8. 51. O'Mahony C, Gomberg M, Skerlev M, Alraddadi A, de las Heras-Alonso ME, Majewski S, et al. Po- sition statement for the diagnosis and manage- ment of anogenital warts. J Eur Acad Dermatol Venereol 2019;33(6):1006-19. 52. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005; 37(6):S3-9. 53. Jablonska S, Orth G, Obalek S, Croissant O. Cuta- neous warts: Clinical, histologic, and virologic correlations. Clin Dermatol 1985;3(4):71-82. 54. Gross G, Pfister H, Hagedorn M, GissmannL. Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Der- matol 1982;78(2):160-4. 55. Wang Y, Chen M, Zhang L, Ding Y, Luo Y, Xu Q, et al. Rapid detection of human papillomavirus using a novel leaky surface acoustic wave pep- tide nucleic acid biosensor. Biosens Bioelectron 2009; 24(12):3455-60. 56. Joh J, Jenson AB, Proctor M, Ingle A, Silva KA, Potter CS, et al. Molecular diagnosis of a labo- ratory mouse papillomavirus (MusPV). Exp Mol Pathol 2012;93(3):416-21. 57. Abreu AL, Souza RP, Gimenes F, Consolaro ME. A review of methods for detecting human papil- lomavirus infection. Virol J 2012;9:262. 58. Das S. Human papillomavirus infection: Man- agement and treatment. In: Human Papillo- mavirus 2020 Aug 7. Intech Open. 59. Messing AM, Epstein WL. Natural history of warts - A two-year study. Arch Dermatol 1963;87:306. 60. Sterling JC. Virus infections. In: Burns T, Breathnach S, Cox N, Griffith C, editors. Rook's Textbook of Dermatology. 7th ed. Oxford: Blackwell Publishing; 2004. p. 25.1-25.83. 61. Von Krogh G. Condylomata acuminata - an up- dated review. Semin Dermatol 1983;2:109-29. 62. Beutner KR, von Krogh G. Current status of podophyllotoxin for the treatment of genital warts. Semin Dermatol 1990;9:148-51. 63. Chamberlain MJ, Reynolds AL, Yeoman WB. Toxic effect of podophyllum application in preg- nancy. Br Med J 1972;3:391-2. 64. Slater GE, Rumack BH, Peterson RG. Podophyllin poisoning - Systemic toxicity following cutaneous application. Obstet Gy- necol 1978;52:94-6. 65. Leslie KO, Shitamoto B. The bone marrow in systemic podophyllin toxicity. Am J Clin Pathol 1982;77:478-80. 66. Epstein WL, Kligman AM. Treatment of warts with cantharidin. AMA Arch Dermatol 1958; 77(5):508-11. 67. Kartal Durmazlar SP, Atacan D, Eskioglu F. Can- tharidin treatment for recalcitrant facial flat warts: a preliminary study. J Dermatol Treat 2009; 20(2):114-9. 68. Miller DM, Brudell RT. Human papilloma in- fection: Treatment options for warts. Am Fam Physician 1996;53:135-43. 69. Al-Hamdi KI, Al-Rahmani MA. Evaluation of topical potassium hydroxide solution for treatment of plane warts. Indian J Dermatol 2012;57(1):38-41. 70. Leman JA, Bentox C. Verrucas. Guidelines for management. Am J Clin Dermatol 2000;1:143-9. 71. Thappa DM, Chiramel MJ. Evolving role of im- munotherapy in the treatment of refractory warts. Indian Dermatol Online J 2016;7(5):364- 70. 72. Mulhem E, Pinelis S. Treatment of nongen- ital cutaneous warts. Am Fam Physician 2011; 84 (3):288-93. 73. Al-Guarairi FT, Al-Waiz M, Sharquie KE. Oral zinc sulphate in the treatment of recalcitrant vi- ral warts: randomized placebo-controlled clin- ical trial. Br J Dermatol 2002;146:423-31. 74. Dall'oglio F, D'Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: an evidence- based review. Am J Clin Dermatol 2012;13(2):73- 96. 75. Gharib K, Taha A, Elradi M. Intralesional acy- clovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a ran- domized controlled trial. Arch Dermatol Res 2024; 316 (6):325. 76. Alkady OH, Khalil KT, Ibrahim SE, Farag RT, Rezk SM. Intralesional injection of mumps, measles, and rubella vaccine, bleomycin, and vitamin D3 in warts treatment. Menoufia Med J 2023;36(3):3. 77. Joshi VD, Pradhan SN, Belgaumkar VA. Eval- uation of efficacy and safety of intralesional vitamin D3 in comparison with intralesional measles, mumps and rubella (MMR) vaccine in the treatment of multiple cutaneous warts. Der- matol Rev 2024;110(6):675-81. 78. Reddy EM, Rajashekar TS, Kumar KS, Reddy ME, Rajashekar TS. A comparative study of intralesional acyclovir vs immunotherapy for treatment of viral warts. Cureus 2023 May 9;15(5). 79. Nofal A, Nofal E, Yosef A, Nofal H. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: A promising ap- proach. Int J Dermatol 2015;54(6):667-71. 80. Naseem R, Aamir S. The efficacy of intrale- sional measles, mumps, rubella (MMR) anti- gen in treatment of common warts. Pak J Med Health Sci 2013;7(4):1130-3. 81. Sobhy Mohamad N, Badran F, Yakout E. Eval- uation of the efficacy of a combination – measles, mumps and rubella vaccine in the treatment of plantar warts. Our Dermatol On- line 2013; 4(4):463-7. 82. Shah A, Patel D, Ravishankar V. Measles, mumps and rubella vaccine as an intralesional immunotherapy in treatment of warts. Int J Res Med Sci 2016;4(2):472-6. 83. Raju J, Swamy AV, Nanjunda Swamy BL, Raghavendra KR. Intralesional measles,mumps and rubella (MMR) vaccine-An effec- tive therapeutic tool in the treatment of wart. J Evid Based Med Healthc 2015 Nov 23;2:8548-51. 84. Rohit V, Gajula N. Role of intralesional measles mumps rubella vaccine in cutaneous warts: A case control study. 2017 Dec;57-60. 85. Chauhan PS, Mahajan VK, Mehta KS, Rawat R, Sharma V. The efficacy and safety of intrale- sional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of com- mon warts in adults. Indian Dermatol Online J 2019 Jan-Feb;10(1):19-26. 86. Aktaş H, Ergin C, Demir B, Ekiz Ö. Intrale- sional vitamin D injection may be an effective treatment option for warts. J Cutan Med Surg 2016; 20 (2):118-22. 87. Jakhar D, Kaur I, Misri R. Intralesional vita- min D3 in periungual warts. J Am Dermatol 2018; 80 (5):e111-e112. 88. Raghukumar S, Ravikumar BC, Vinay KN, Suresh MR, Aggarwal A, Yashovardhana DP. In- tralesional Vitamin D3 injection in the treat- ment of recalcitrant warts: A novel proposition. J Cutan Med Surg 2017;21(4):320-4. 89. Kareem IMA, Ibrahim IM, Mohammed SFF, Ahmed AA. Effectiveness of intralesional vita- min D3 injection in the treatment of common warts: Single blinded placebo controlled study. Dermatol Ther 2019;32(2):e12882. 90. El-Taweel AEA, Salem RM, Allam AH. Cigarette smoking reduces the efficacy of intralesional vi- tamin D in the treatment of warts. Dermatol Ther 2019;32(2):122. 91. Nofal A, Nofal E. Intralesional immunother- apy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol 2010;24(10):1166-70.